Enoxaparin Sandoz

DVT. Unstable angina & non-Q-wave MI administered concurrently w/ aspirin. Acute ST-segment elevation MI (STEMI) in combination w/ thrombolytic agent in patients to be managed medically or w/ subsequent percutaneous coronary intervention (PCI). Prevention of thrombus formation in extracorporeal circulation during haemodialysis. Prophylaxis of venous thromboembolic disease particularly those which may be associated w/ orthopedic or general surgery. Prophylaxis of venous thromboembolic disease in medical patients bedridden due to acute illnesses.

SC DVT 100 anti-Xa IU/kg every 12 hr. Unstable angina & non-Q-wave MI 100 anti-Xa IU/kg every 12 hr administered concurrently w/ oral aspirin (100-325 mg once daily). Prophylaxis of venous thromboembolic disease Surgical patient 2,000 anti-Xa IU once daily, 1st inj should be given 2 hr before surgical procedure. Patient w/ high risk of thromboembolic (eg, orthopedic surgery) 4,000 anti-Xa IU once daily initiated 12 hr pre-op. Medical patient 4,000 anti-Xa IU once daily. Min duration: 6 days. Max duration: 14 days. IV/SC Acute STEMI in combination w/ thrombolytic agent Patient eligible or not for subsequent PCI Initially 3,000 anti-Xa IU IV bolus inj followed by 100 anti-Xa IU/kg SC w/in 15 min then every 12 hr. Max: 10,000 anti-Xa IU for each of the 1st 2 SC doses only, followed by 100 anti-Xa/kg IU SC for the remaining doses. Patient managed w/ PCI Administer 30 anti-Xa IU/kg IV bolus if last SC inj was performed >8 hr before balloon inflation. Elderly ≥75 yr eligible or not for subsequent PCI 75 anti-Xa IU/kg SC every 12 hr. Max: 7,500 anti-Xa IU for each of the 1st 2 doses only, followed by 75 anti-Xa IU/kg for the remaining doses. Intra-arterial Prevention of extracorporeal thrombus formation during haemodialysis 100 anti-Xa IU/kg at beginning of dialysis. Further dose of 50-100 anti-Xa IU/kg may be given if fibrin rings are found (eg, after longer than normal sessions). Patient at high risk of haemorrhage Reduce to 50 anti-Xa IU/kg for double vascular access or 75 anti-Xa IU/kg for single vascular access.

Hypersensitivity to enoxaparin sodium, heparin or other LMWH. Acute bacteria endocarditis. Active major bleeding disorders & conditions w/ high risk of uncontrolled haemorrhage including recent hemorrhagic stroke. Thrombocytopenia in patients w/ +ve in vitro aggregation test in presence of enoxaparin. Acute gastric or duodenal ulceration.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AB05 - enoxaparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.

POM